APA (7th ed.) Citation

Hwang, I., Kim, J. E., Jeong, J. H., Ahn, J., Jung, K. H., Son, B. H., . . . Kim, S. (2023). Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506). Breast cancer research and treatment, 201(2), 193-204. https://doi.org/10.1007/s10549-023-06971-7

Chicago Style (17th ed.) Citation

Hwang, Inhwan, et al. "Randomized Phase III Trial of a Neoadjuvant Regimen of Four Cycles of Adriamycin Plus Cyclophosphamide Followed by Four Cycles of Docetaxel (AC4-D4) Versus a Shorter Treatment of Three Cycles of FEC Followed by Three Cycles of Docetaxel (FEC3-D3) in Node-positive Breast Cancer (Neo-shorter; NCT02001506)." Breast Cancer Research and Treatment 201, no. 2 (2023): 193-204. https://doi.org/10.1007/s10549-023-06971-7.

MLA (9th ed.) Citation

Hwang, Inhwan, et al. "Randomized Phase III Trial of a Neoadjuvant Regimen of Four Cycles of Adriamycin Plus Cyclophosphamide Followed by Four Cycles of Docetaxel (AC4-D4) Versus a Shorter Treatment of Three Cycles of FEC Followed by Three Cycles of Docetaxel (FEC3-D3) in Node-positive Breast Cancer (Neo-shorter; NCT02001506)." Breast Cancer Research and Treatment, vol. 201, no. 2, 2023, pp. 193-204, https://doi.org/10.1007/s10549-023-06971-7.